🇮🇳 NEET SS · subject

NEET SS Medical Oncology (DM) Syllabus

The Medical Oncology (DM) syllabus for NEET SS in full: 4 chapters, 14 topics and 20 sub-topics, every one listed below, plus 51 Medical Oncology (DM) flashcards with answers.

4Chapters
14Topics
20Sub-topics
51Flashcards

Medical Oncology (DM) syllabus: all 4 chapters

Expand any chapter to see its topics and sub-topics.

  1. Principles of Cancer Biology and Therapeutics

    4 topics
    • Hallmarks of Cancer and Carcinogenesis
      • Oncogenes and tumor suppressor genes
      • Tumor microenvironment and angiogenesis
    • Principles of Chemotherapy
      • Drug classes and mechanisms
      • Toxicity management
    • Targeted Therapy and Immunotherapy
      • Tyrosine kinase inhibitors
      • Immune checkpoint inhibitors and irAEs
    • Cancer Screening, Staging and Prevention
      • TNM staging principles
  2. Solid Tumors

    4 topics
    • Thoracic and Head-Neck Cancers
      • Lung cancer molecular subtypes
    • Gastrointestinal Malignancies
      • Colorectal, gastric and hepatobiliary cancers
    • Breast and Gynecological Cancers
      • Hormone receptor and HER2 status
    • Genitourinary and CNS Tumors
      • Prostate and renal cell carcinoma
  3. Hematological Malignancies

    3 topics
    • Acute and Chronic Leukemias
      • AML, ALL classification and therapy
      • CML and tyrosine kinase inhibitors
    • Lymphomas
      • Hodgkin and non-Hodgkin lymphoma
    • Plasma Cell Disorders
      • Multiple myeloma
  4. Supportive and Palliative Oncology

    3 topics
    • Oncologic Emergencies
      • Tumor lysis syndrome and febrile neutropenia
      • Spinal cord compression and SVC obstruction
    • Supportive Care
      • Antiemetics and growth factors
      • Cancer pain management
    • Paraneoplastic Syndromes
      • Endocrine and neurologic syndromes

NEET SS Medical Oncology (DM) flashcards — 51 questions with answers

  1. What are the eight core Hallmarks of Cancer described by Hanahan and Weinberg (2011), beyond the original six?

    Original six: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion/metastasis. Two emerging: deregulating cellular energetics (Warburg effect) and avoiding immune destruction. Two enabling characteristics: genome instability/mutation and tumor-promoting inflammation.

  2. What is the Warburg effect in cancer metabolism?

    The preference of tumor cells for aerobic glycolysis (glucose to lactate) even in the presence of oxygen, rather than oxidative phosphorylation; it supports rapid biosynthesis and is the basis of FDG-PET imaging.

  3. Define the three stages of chemical carcinogenesis.

    Initiation (irreversible DNA mutation by a carcinogen), promotion (reversible clonal expansion of initiated cells by promoters), and progression (acquisition of malignant phenotype with genetic instability and invasion).

  4. Differentiate oncogenes from tumor suppressor genes, including inheritance pattern of mutations.

    Oncogenes are gain-of-function, dominant (one mutated allele sufficient), e.g. RAS, MYC, HER2. Tumor suppressors are loss-of-function, recessive at cellular level requiring biallelic inactivation (Knudson two-hit hypothesis), e.g. TP53, RB1, APC.

  5. What classes of viruses are linked to human cancers, with one example each?

    HPV (cervical, oropharyngeal), HBV/HCV (hepatocellular carcinoma), EBV (Burkitt lymphoma, nasopharyngeal carcinoma, Hodgkin), HHV-8 (Kaposi sarcoma), HTLV-1 (adult T-cell leukemia/lymphoma), Merkel cell polyomavirus (Merkel cell carcinoma).

  6. Describe the cell-cycle phase specificity of antimetabolites versus alkylating agents.

    Antimetabolites (e.g. methotrexate, 5-FU, cytarabine) are S-phase specific (cell-cycle phase-specific). Alkylating agents (e.g. cyclophosphamide, cisplatin) are cell-cycle phase-nonspecific, acting in all phases including G0.

  7. What is the log-kill hypothesis (Skipper) in chemotherapy?

    A given dose of chemotherapy kills a constant fraction (not a constant number) of tumor cells, regardless of tumor burden; this first-order kinetics rationale underlies multiple cyclical dosing to reduce tumor burden by successive logs.

  8. State the dose-limiting and characteristic toxicities of anthracyclines (e.g. doxorubicin).

    Cumulative dose-dependent cardiotoxicity (dilated cardiomyopathy/CHF, lifetime limit ~450-550 mg/m2); also myelosuppression, mucositis, alopecia, vesicant extravasation, and red urine. Dexrazoxane is cardioprotective.

  9. Match these chemotherapy drugs to their signature non-hematologic toxicities: cisplatin, bleomycin, vincristine, cyclophosphamide.

    Cisplatin: nephrotoxicity, ototoxicity, peripheral neuropathy. Bleomycin: pulmonary fibrosis. Vincristine: peripheral neuropathy (no myelosuppression). Cyclophosphamide: hemorrhagic cystitis (prevented by mesna).

  10. What is the mechanism of action of taxanes and vinca alkaloids on microtubules?

    Taxanes (paclitaxel, docetaxel) stabilize microtubules preventing depolymerization; vinca alkaloids (vincristine, vinblastine) bind tubulin and inhibit microtubule assembly/polymerization. Both arrest cells in M phase (mitotic spindle poisons).

  11. Name the targeted agent and its target for: CML, HER2-positive breast cancer, EGFR-mutant lung cancer, and BCR-ABL-independent BRAF V600E melanoma.

    CML: imatinib (BCR-ABL tyrosine kinase). HER2 breast: trastuzumab (HER2/ERBB2). EGFR lung: gefitinib/osimertinib (EGFR). BRAF melanoma: vemurafenib/dabrafenib (BRAF V600E).

  12. How do immune checkpoint inhibitors work, and name the main targets?

    They block inhibitory immune checkpoints to restore T-cell antitumor activity. Targets: CTLA-4 (ipilimumab), PD-1 (nivolumab, pembrolizumab), and PD-L1 (atezolizumab, durvalumab).

  13. What is CAR-T cell therapy and a key approved indication?

    Chimeric Antigen Receptor T-cell therapy: patient T-cells are genetically engineered to express a receptor against a tumor antigen (e.g. CD19) and reinfused. Approved for relapsed/refractory B-ALL and B-cell lymphomas (e.g. tisagenlecleucel, axicabtagene).

  14. What is cytokine release syndrome (CRS), the major toxicity of CAR-T therapy, and its treatment?

    A systemic inflammatory response from massive cytokine release (high IL-6) causing fever, hypotension, hypoxia, and organ dysfunction; treated with tocilizumab (anti-IL-6 receptor) and corticosteroids.

  15. List the recommended screening tests and target populations for breast, cervical, and colorectal cancer.

    Breast: mammography every 1-2 years from age 40-50. Cervical: Pap smear/HPV testing from age 21-25 every 3-5 years. Colorectal: colonoscopy every 10 years (or FIT/FOBT annually) from age 45-50.

  16. Explain the TNM staging system components.

    T = size/extent of primary Tumor (T1-T4), N = regional lymph Node involvement (N0-N3), M = distant Metastasis (M0/M1). These combine into stage groups I-IV.

  17. Define lead-time bias and length-time bias in cancer screening.

    Lead-time bias: apparent increase in survival because diagnosis is earlier, without changing time of death. Length-time bias: screening preferentially detects slow-growing, indolent tumors with better prognosis, overstating screening benefit.

  18. What tumor markers are used for: ovarian, prostate, colorectal, hepatocellular, and testicular cancers?

    Ovarian: CA-125. Prostate: PSA. Colorectal: CEA. Hepatocellular: AFP. Testicular: AFP and beta-hCG (plus LDH).

  19. What is the most common type of lung cancer, and which subtype is most associated with smoking and central location with paraneoplastic syndromes?

    Adenocarcinoma is the most common (and most common in non-smokers, peripheral). Small cell lung cancer (SCLC) is strongly smoking-associated, central, and causes paraneoplastic syndromes (SIADH, ectopic ACTH, Lambert-Eaton).

  20. What is the most common cause of head and neck squamous cell carcinoma, and what biomarker confers better prognosis in oropharyngeal cancer?

    Tobacco and alcohol are classic causes; HPV (p16-positive) oropharyngeal cancer has a significantly better prognosis and treatment response.

Show the other 31 Medical Oncology (DM) flashcards
  1. Name the molecular subtypes/key biomarkers tested in colorectal cancer that guide therapy.

    RAS (KRAS/NRAS) and BRAF mutation status (anti-EGFR antibodies like cetuximab work only in RAS wild-type), and microsatellite instability (MSI-H/dMMR), which predicts immunotherapy response and Lynch syndrome.

  2. What is the Barcelona Clinic Liver Cancer (BCLC) significance and first-line systemic therapy for advanced HCC?

    BCLC staging integrates tumor stage, liver function (Child-Pugh), and performance status to guide HCC treatment. First-line systemic therapy for advanced HCC is atezolizumab plus bevacizumab.

  3. Which gene mutation is associated with gastrointestinal stromal tumors (GIST) and what targeted drug is used?

    Activating mutations in KIT (CD117) or PDGFRA; treated with imatinib (and sunitinib/regorafenib for resistance).

  4. Define the molecular subtypes of breast cancer based on receptor status.

    Luminal A (ER+/PR+, HER2-, low Ki-67), Luminal B (ER+, higher Ki-67 or HER2+), HER2-enriched (ER-/HER2+), and Triple-negative/Basal-like (ER-/PR-/HER2-).

  5. What hereditary syndrome predisposes to breast and ovarian cancer, and what therapy exploits this defect?

    BRCA1/BRCA2 germline mutations (hereditary breast-ovarian cancer syndrome); PARP inhibitors (olaparib, niraparib) exploit synthetic lethality in homologous recombination-deficient tumors.

  6. What is the most common gynecological malignancy in developed countries and its main risk factor?

    Endometrial (uterine) carcinoma; main risk factor is unopposed estrogen exposure (obesity, nulliparity, late menopause, tamoxifen, PCOS).

  7. What is the Gleason score in prostate cancer and what does it indicate?

    A histologic grading system summing the two most prevalent Gleason patterns (each 1-5), giving a score of 6-10; higher scores indicate more aggressive, poorly differentiated tumors with worse prognosis.

  8. Name the most common renal cell carcinoma subtype and its associated genetic alteration.

    Clear cell renal cell carcinoma; associated with VHL (von Hippel-Lindau) gene inactivation on chromosome 3p, leading to HIF accumulation and angiogenesis.

  9. What is the most common primary malignant brain tumor in adults, and its key prognostic molecular markers?

    Glioblastoma (GBM, WHO grade 4 astrocytoma). Better prognosis with IDH mutation and MGMT promoter methylation (predicts temozolomide response).

  10. Differentiate AML from ALL by typical age, common cytochemistry, and a defining cytogenetic example.

    AML: adults, myeloperoxidase-positive, Auer rods; t(15;17) in APL (M3). ALL: children, TdT-positive, PAS-positive; t(9;22) Philadelphia chromosome confers poor prognosis (treated with TKI).

  11. What is the treatment and pathognomonic emergency of acute promyelocytic leukemia (APL, AML-M3)?

    Treated with ATRA (all-trans retinoic acid) plus arsenic trioxide. Pathognomonic emergency: DIC (disseminated intravascular coagulation) from release of procoagulants; ATRA can also cause differentiation syndrome.

  12. What defines chronic myeloid leukemia and the three clinical phases?

    Defined by BCR-ABL1 fusion (Philadelphia chromosome, t(9;22)) producing constitutive tyrosine kinase. Phases: chronic phase, accelerated phase, and blast crisis (>20% blasts). First-line therapy: TKIs (imatinib, dasatinib, nilotinib).

  13. What is the most common adult leukemia in the West, its immunophenotype, and a poor-prognosis marker?

    Chronic lymphocytic leukemia (CLL); CD5+, CD19+, CD23+ B cells with smudge cells on smear; del(17p)/TP53 mutation indicates poor prognosis and resistance to chemoimmunotherapy.

  14. How are Hodgkin and non-Hodgkin lymphoma distinguished pathologically and by spread?

    Hodgkin lymphoma has Reed-Sternberg cells (CD15+, CD30+), spreads contiguously between nodal groups, and has bimodal age distribution. NHL lacks Reed-Sternberg cells, spreads non-contiguously/extranodally, and is more common.

  15. What is the most common non-Hodgkin lymphoma in adults and its first-line treatment?

    Diffuse large B-cell lymphoma (DLBCL); treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone).

  16. Name the translocations characteristic of Burkitt lymphoma, follicular lymphoma, and mantle cell lymphoma.

    Burkitt: t(8;14) c-MYC. Follicular: t(14;18) BCL2. Mantle cell: t(11;14) cyclin D1 (BCL1).

  17. What is the CRAB criteria for symptomatic multiple myeloma?

    hyperCalcemia, Renal insufficiency, Anemia, Bone lesions (lytic). These end-organ damage features distinguish active myeloma requiring treatment from MGUS/smoldering myeloma.

  18. What laboratory and imaging findings support a diagnosis of multiple myeloma?

    Monoclonal (M) protein spike on serum/urine electrophoresis (Bence Jones proteins), >10% clonal plasma cells in marrow, rouleaux formation, lytic 'punched-out' bone lesions, and elevated free light chains.

  19. Define MGUS and its relationship to multiple myeloma.

    Monoclonal Gammopathy of Undetermined Significance: M protein <3 g/dL, <10% marrow plasma cells, no CRAB features. It is a premalignant condition that progresses to multiple myeloma at ~1% per year.

  20. What is tumor lysis syndrome, its classic metabolic abnormalities, and prophylaxis?

    Massive tumor cell death (often after chemo of bulky/high-turnover tumors) causing hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia, leading to acute kidney injury/arrhythmia. Prophylaxis: aggressive hydration, allopurinol or rasburicase.

  21. What is the management of malignant hypercalcemia?

    Aggressive IV isotonic saline hydration, IV bisphosphonates (zoledronic acid) or denosumab; calcitonin for rapid short-term lowering; treat the underlying malignancy. PTHrP-mediated humoral hypercalcemia is the most common mechanism.

  22. What are the features and emergency management of malignant spinal cord compression?

    Back pain (worse at night/recumbent), motor weakness, sensory level, and bladder/bowel dysfunction. Emergency: high-dose dexamethasone immediately, urgent MRI of whole spine, then radiotherapy or surgical decompression.

  23. What is superior vena cava (SVC) syndrome, its most common malignant cause, and management?

    Obstruction of SVC causing facial/upper limb edema, distended neck veins, and dyspnea. Most common malignant cause is lung cancer (especially SCLC) and lymphoma. Management: airway support, corticosteroids, radiotherapy/chemotherapy, and endovascular stenting.

  24. What is febrile neutropenia, its definition, and initial management?

    Temperature >=38.3C once (or >=38.0C sustained 1 hour) with absolute neutrophil count <500 (or <1000 falling). Emergency: blood cultures then immediate empiric broad-spectrum IV antibiotics (anti-pseudomonal beta-lactam e.g. piperacillin-tazobactam or cefepime) within 1 hour.

  25. What is the role and main agents of G-CSF (granulocyte colony-stimulating factor) in oncology?

    G-CSF (filgrastim, pegfilgrastim) stimulates neutrophil production to prevent/treat chemotherapy-induced neutropenia and for stem cell mobilization. Used as primary prophylaxis when febrile neutropenia risk is >20%.

  26. Classify chemotherapy emetogenicity management: name the antiemetic triple therapy for highly emetogenic regimens.

    A 5-HT3 antagonist (ondansetron/palonosetron) + NK1 antagonist (aprepitant) + dexamethasone; olanzapine may be added as a fourth agent for highly emetogenic chemotherapy like cisplatin.

  27. What is SIADH as a paraneoplastic syndrome, its classic associated tumor, and treatment?

    Syndrome of Inappropriate ADH secretion causing euvolemic hyponatremia with concentrated urine; classically caused by small cell lung cancer. Treatment: fluid restriction, and vaptans or hypertonic saline for severe symptomatic hyponatremia.

  28. What paraneoplastic syndrome causes Cushing's, and which tumor most commonly produces ectopic ACTH?

    Ectopic ACTH syndrome causes hypokalemic metabolic alkalosis, hyperglycemia, and Cushingoid features; small cell lung cancer (and bronchial carcinoid) is the classic source.

  29. What is Lambert-Eaton myasthenic syndrome, its mechanism, and association?

    A paraneoplastic neuromuscular disorder from autoantibodies against presynaptic voltage-gated calcium channels causing proximal weakness that improves with repeated effort; associated with small cell lung cancer.

  30. Match these paraneoplastic syndromes to tumors: hypercalcemia (PTHrP), polycythemia (erythropoietin), and acanthosis nigricans.

    PTHrP hypercalcemia: squamous cell carcinoma of lung, renal cell, head/neck. Erythropoietin polycythemia: renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma. Acanthosis nigricans: gastric adenocarcinoma.

  31. What is the difference between neoadjuvant, adjuvant, and palliative chemotherapy?

    Neoadjuvant: given before primary (surgical) therapy to shrink the tumor and improve resectability. Adjuvant: given after definitive local therapy to eradicate micrometastases and reduce recurrence. Palliative: given to relieve symptoms and prolong life in incurable disease, prioritizing quality of life.

NEET SS Medical Oncology (DM) FAQ

What is in the NEET SS Medical Oncology (DM) syllabus?

NEET SS Medical Oncology (DM) is split into 4 chapters: Principles of Cancer Biology and Therapeutics, Solid Tumors, Hematological Malignancies and Supportive and Palliative Oncology. Together they contain 14 topics and 20 sub-topics.

How many chapters are in NEET SS Medical Oncology (DM)?

4 chapters, containing 14 topics and 20 sub-topics. The largest chapter is Principles of Cancer Biology and Therapeutics, with 4 topics.

Are there flashcards for NEET SS Medical Oncology (DM)?

Yes — a 51-card Medical Oncology (DM) deck, printed in full in the flashcards section of this page and available in the Examius app with spaced repetition. The free plan covers one exam of your choice, including its flashcards; Examius Pro, a one-time purchase, unlocks every other exam and deck.